RT Journal Article
SR Electronic
T1 Correction: <em>Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma</em>
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e000391corr1
DO 10.1136/jitc-2019-000391corr1
VO 8
IS 2
YR 2020
UL http://jitc.bmj.com/content/8/2/e000391corr1.abstract